A pair of Medicare Part D drug pricing measures emerging from Congress and the Administration could act as financial offsets to an extent in terms their impact on biopharma manufacturers.
Manufacturers face a substantial increase in the price discounts they are required to provide for drugs obtained by beneficiaries in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?